cefuzonam profile

cefuzonam: article gives L-105 as synonym, however L 105 is a rifamycin derivative according to Chemline [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefuzonam : A second generation cephalosporin antibiotic. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6336505
CHEMBL ID	1689069
CHEBI ID	55488
SCHEMBL ID	149484
MeSH ID	M0142851

Synonym
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-3-[(1,2,3-thiadiazol-5-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEBI:55488 ,
7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1,2,3-thiadiazol-5-ylsulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
cefuzonamum
cefuzonam
cefuzonam (inn)
82219-78-1
D03432
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(thiadiazol-5-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEMBL1689069
(-)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-((1,2,3-thiadiazol-5-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-(o-methyloxime)
860mt00t7t ,
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-((1,2,3-thiadiazol-5-ylthio)methyl)-, (6r-(6alpha,7beta(z)))-
unii-860mt00t7t
cefuzonam [inn]
cefuzonamum [latin]
AKOS016013940
cefuzonam [who-dd]
cefuzonam [mi]
cefuzonam [mart.]
SCHEMBL149484
DTXSID8048282

Excerpt	Reference	Relevance
"Cefuzonam (CZON) which has a broad spectrum on both Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus was evaluated in severe infections associated with hematological disorders. "	( [Clinical evaluation of cefuzonam of severe infections in leukemia and related disorders]. Fujii, H; Kashima, K; Misawa, S; Nakagawa, H; Nishigaki, H; Okuda, T; Tanaka, S; Taniwaki, M; Tsuda, S; Yashige, H, 1990)	2.03
"Cefuzonam (CZON) which has a broad spectrum on both Gram-negative and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus was evaluated in severe infections associated with hematological disorders. "	( [Clinical evaluation of cefuzonam of severe infections in leukemia and related disorders]. Fujii, H; Kashima, K; Misawa, S; Nakagawa, H; Nishigaki, H; Okuda, T; Tanaka, S; Taniwaki, M; Tsuda, S; Yashige, H, 1990)	2.03

Excerpt	Reference	Relevance
" Following one shot intravenous injection of CZON 1 g, a good distribution of the drug into tissues of uterus and uterine adnexa was observed, with Cmax values of 15."	( [Pharmacokinetic, bacteriological and clinical studies on cefuzonam in the field of obstetrics and gynecology]. Arihiro, T; Hachiya, S; Hayashi, M; Hayashi, S; Koike, K; Morimoto, O; Obata, I; Tsuruoka, N; Yamato, T, 1987)	0.52

Excerpt	Relevance	Reference
"Cefuzonam (CZON, L-105) was used clinically for the treatment of obstetrical and gynecological infections at a dosage of 1 g once or twice daily by intravenous drip infusion."	( [Clinical study of cefuzonam in the field of obstetrics and gynecology]. Fujiwara, A; Hara, T; Masaoka, T; Naito, H; Urabe, T; Yamanaka, S, 1988)	2.05
" The CZON was administered in 3 or 4 divided doses at a daily dosage ranging from 58."	( [Clinical evaluation of cefuzonam in children]. Mayumi, M; Mikawa, H; Mochizuki, Y; Ohkubo, H; Yoshida, A, 1987)	0.58
"Analysis on serum concentrations of cefuzonam (CZON, L-105) in 7 children who received different doses of CZON revealed a dose-response relationship."	( [Clinical studies of cefuzonam in the pediatric field]. Goto, Y; Kida, K; Matsuda, H; Murase, M, 1987)	0.87
" Dosage levels per day were 50 to 80 mg/kg in most cases."	( [Evaluation of cefuzonam in the pediatric field]. Chikaoka, H; Kamigaki, M; Koido, R; Matsumoto, K; Nakada, Y; Nakazawa, S; Narita, A; Sato, H; Suzuki, H, 1987)	0.63
" after injection, and mean values of 3 groups with 10, 20 and 40 mg/kg dosing were 57."	( [Pharmacokinetic and clinical studies of cefuzoname in the pediatric field]. Fujimoto, T; Koga, T; Motohiro, T; Nakano, M; Nishiyama, T; Shimada, Y; Takajo, N; Tominaga, K; Tomita, S; Yamashita, F, 1987)	0.54

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
cephalosporin	A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (47)

Assay ID	Title	Year	Journal	Article
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID587967	Activity of Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587962	Activity of Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587980	Antibacterial activity against Escherichia coli AS226 carrying pBSDS237A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID587966	Activity of Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID587961	Activity of Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID587970	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587964	Activity of Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587974	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587969	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587981	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240S mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587973	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587965	Activity of Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587963	Activity of Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587959	Activity of Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587975	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID587985	Antibacterial activity against Escherichia coli AS226 carrying pBSD6 mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID587983	Antibacterial activity against Escherichia coli AS226 carrying pBSDC69A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID587986	Antibacterial activity against Escherichia coli AS226 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID587979	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104D mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID587978	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587960	Activity of Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID587968	Ratio of Kcat to Km for Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587976	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID587971	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID587984	Antibacterial activity against Escherichia coli AS226 carrying pBSDF160T mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID587977	Antibacterial activity against Escherichia coli AS226 carrying pBSD-H2 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID587982	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID587972	Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	52 (61.18)	18.7374
1990's	30 (35.29)	18.2507
2000's	1 (1.18)	29.6817
2010's	1 (1.18)	24.3611
2020's	1 (1.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (10.23%)	5.53%
Reviews	2 (2.27%)	6.00%
Case Studies	14 (15.91%)	4.05%
Observational	0 (0.00%)	0.25%
Other	63 (71.59%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	3.08	1	0
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	1.97	1	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	1.99	1	0	pentacarboxylic acid	copper chelator
famotidine Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.	1.97	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2.06	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.41	2	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.08	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.41	2	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	6.96	1	0	penicillin allergen; penicillin	antibacterial drug
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	7.7	3	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	1.99	1	0	f-block element atom; lanthanoid atom
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	2.67	3	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	6.97	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	7.38	2	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	1.98	1	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	2.38	2	0	penicillin allergen; penicillin	antibacterial drug
cefotiam Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.	4.61	6	1	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	8.07	5	0	cephalosporin	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	8.72	56	3	cephalosporin	fungal metabolite
flomoxef flomoxef: structure given in first source; RN given refers to sodium salt. flomoxef : A second-generation oxacephem antibiotic in which the oxazine ring is substituted at C-3 with a hydroxyethyl-substituted tetrazolylthiomethyl group and the azetidinone ring carries 7alpha-methoxy and 7beta-{2-[(difluoromethyl)thiomethyl]acetamido} substituents.	3.23	6	0	N-acyl-amino acid; organonitrogen heterocyclic antibiotic; oxacephem	antibacterial drug
arbekacin arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.	7.38	2	0	aminoglycoside; kanamycins	antibacterial agent; antibacterial drug; antimicrobial agent; protein synthesis inhibitor
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	1.98	1	0
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.24	6	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
sulbactam [no description available]	7.39	2	0	penicillanic acids
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	1.99	1	0	beta-lactam antibiotic allergen; beta-lactam
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	2.06	1	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	1.97	1	0
sultamicillin sultamicillin: contains ampicillin & sulbactam	1.99	1	0	penicillanic acid ester
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	2.38	2	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	1.96	1	0	cephalosporin; semisynthetic derivative	antibacterial drug
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	2.38	2	0	kanamycins	antibacterial agent; protein synthesis inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	6.97	1	0	cephalosporin; oxime O-ether	antibacterial drug
ceftazidime [no description available]	2.06	1	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	9.75	7	1	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	2.06	1	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cilastatin [no description available]	6.97	1	0	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
cefclidin cefclidin: structure given in first source. cefclidin : A fourth-generation cephalosporin antibiotic having (4-carbamoyl-1-azoniabicyclo[2.2.2]octan-1-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	1.97	1	0	cephalosporin; thiadiazoles
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	3.08	1	0	monobactam	antibacterial drug
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	1.99	1	0	gadolinium coordination entity	MRI contrast agent
cefmenoxime Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmenoxime : A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.	4.05	3	1	cephalosporin	antibacterial drug
cp 70429 sulopenem: a penem antibiotic	2.39	2	0
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	1.98	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.67	3	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	1.97	1	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies	Trials
Complications, Infectious Pregnancy [description not available]	3.81	2	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	4.07	3	1
Infections, Pneumococcal [description not available]	1.98	1	0
Bacterial Endocarditides [description not available]	1.98	1	0
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	1.98	1	0
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	1.98	1	0
Middle Ear Inflammation [description not available]	2.39	2	0
Sinus Infections [description not available]	1.98	1	0
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	2.39	2	0
Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.	1.98	1	0
Tonsillitis Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.	2.38	2	0
Infections, Staphylococcal [description not available]	2.66	3	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.66	3	0
Brain Disorders [description not available]	1.98	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	1.98	1	0
Cranial Nerve Diseases Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.	1.99	1	0
Palsy [description not available]	1.99	1	0
Symptom Cluster [description not available]	1.99	1	0
Mastoiditis Inflammation of the honeycomb-like MASTOID BONE in the skull just behind the ear. It is usually a complication of OTITIS MEDIA.	1.99	1	0
Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)	1.99	1	0
Syndrome A characteristic symptom complex.	1.99	1	0
E coli Infections [description not available]	2.38	2	0
Infections, Klebsiella [description not available]	1.99	1	0
Disease, Pulmonary [description not available]	2.38	2	0
Bacteroides Infections Infections with bacteria of the genus BACTEROIDES.	1.99	1	0
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.38	2	0
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	1.99	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	2.38	2	0
Autosomal Recessive Chronic Granulomatous Disease [description not available]	2.89	1	0
Periostitis Inflammation of the periosteum. The condition is generally chronic, and is marked by tenderness and swelling of the bone and an aching pain. Acute periostitis is due to infection, is characterized by diffuse suppuration, severe pain, and constitutional symptoms, and usually results in necrosis. (Dorland, 27th ed)	2.89	1	0
Splenic Diseases Diseases involving the SPLEEN.	2.89	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	2.89	1	0
Granulomatous Disease, Chronic A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.	2.89	1	0
Bacterial Disease [description not available]	8.94	44	6
Blood Diseases [description not available]	4.33	2	2
Bacterial Infections Infections by bacteria, general or unspecified.	8.94	44	6
Hematologic Diseases Disorders of the blood and blood forming tissues.	4.33	2	2
Chronic Kidney Failure [description not available]	1.97	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	1.97	1	0
Perforated Appendicitis [description not available]	8.36	1	1
Primary Peritonitis [description not available]	3.36	1	1
Rupture, Spontaneous Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.	3.36	1	1
Intestinal Perforation Opening or penetration through the wall of the INTESTINES.	3.36	1	1
Acute Disease Disease having a short and relatively severe course.	4.05	3	1
Appendicitis Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.	8.36	1	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	8.36	1	1
Empyema, Gall Bladder [description not available]	1.97	1	0
Gallstone Disease [description not available]	1.97	1	0
Complication, Postoperative [description not available]	1.97	1	0
Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.	1.97	1	0
Cholelithiasis Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).	1.97	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	1.97	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	4.61	6	1
Pneumonia Infection of the lung often accompanied by inflammation.	4.61	6	1
Abscess, Pulmonary [description not available]	3.36	1	1
Lung Abscess Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.	8.36	1	1
Group A Strep Infection [description not available]	1.97	1	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	1.97	1	0
Leucocythaemia [description not available]	3.36	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	8.36	1	1
Cataract, Membranous [description not available]	1.97	1	0
Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)	1.97	1	0
Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)	1.97	1	0
Cancer of Lung [description not available]	1.97	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	1.97	1	0
Endometrial Diseases [description not available]	4.27	4	1
Uterine Diseases Pathological processes involving any part of the UTERUS.	4.27	4	1
Adnexitis Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).	3.76	2	1
Pelvic Inflammatory Disease A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES; (SALPINGITIS); the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility.	3.76	2	1
Chronic Illness [description not available]	3.76	2	1
Infections, Respiratory [description not available]	3.76	2	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.76	2	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	8.76	2	1
Pus [description not available]	1.96	1	0
Fibroid [description not available]	1.97	1	0
Cancer of the Uterus [description not available]	1.97	1	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	1.97	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	1.97	1	0
Female Genital Diseases [description not available]	6.05	16	2
Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).	6.05	16	2
Pachymeningitis [description not available]	2.88	4	0
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	2.88	4	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	3.06	5	0
Biliary Tract Diseases Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.	1.97	1	0
Empyema Presence of pus in a hollow organ or body cavity.	2.37	2	0
Adenitis [description not available]	1.97	1	0
Enteritis Inflammation of any segment of the SMALL INTESTINE.	1.97	1	0
Arthritides, Bacterial [description not available]	1.97	1	0
Laryngitis Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.	1.97	1	0
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	1.97	1	0
Infection, Puerperal [description not available]	1.97	1	0

cefuzonam

Description

Cross-References

Synonyms (22)

Research Excerpts

Effects

Pharmacokinetics

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (1)

Other Measurements

Bioassays (47)

Research

Studies (85)

Market Indicators

Research Demand Index: 15.12

Study Types

cefuzonam

Description

Cross-References

Synonyms (22)

Research Excerpts

Effects

Pharmacokinetics

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (1)

Other Measurements

Bioassays (47)

Research

Studies (85)

Market Indicators

Research Demand Index: 15.12

Study Types

Related Drugs (44)

Related Conditions (91)